1063 patents
Page 17 of 54
Utility
Bromodomain Inhibitors
6 Oct 22
The present invention relates to substituted heterocyclic derivative compounds, compositions comprising said compounds, and the use of said compounds and compositions for epigenetic regulation by inhibition of bromodomain-mediated recognition of acetyl lysine regions of proteins, such as histones.
Amogh Boloor
Filed: 31 Dec 20
Utility
Aminotriazolopyridines As Kinase Inhibitors
6 Oct 22
Junqing Guo, Amy C. Hart, John E. Macor, Michael E. Mertzman, William J. Pitts, Steven H. Spergel, Scott Hunter Watterson, Murugaiah Andappan Murugaiah Subbaiah, Jie Chen, Carolyn Diane Dzierba, Guanglin Luo, Jianliang Shi, Sing-Yuen Sit
Filed: 9 Dec 20
Utility
ANTI-PD-1 Antibody for Use In a Method of Treating a Tumor
6 Oct 22
This disclosure provides a method for treating a subject afflicted with tumor, which method comprises administering to the subject an antibody or an antigen-binding portion thereof that specifically binds to a Programmed Death-1 (PD-1) receptor and inhibits PD-1 activity.
Robin EDWARDS, Han CHANG, Michele CLEARY, Peter M. SZABO, Joseph Daniel SZUSTAKOWSKI, Patrik VITAZKA
Filed: 21 Mar 22
Utility
Methods of Improving Protein Productivity In Fed-batch Cell Cultures
6 Oct 22
In certain embodiments, this disclosure provides a method of increasing production of a recombinant polypeptide of interest, comprising: a) seeding mammalian cells in a fed-batch production bioreactor at a viable cell density of at least 5106 viable cells/ml; and b) culturing the cells under optimized culture conditions to produce the recombinant polypeptide of interest at high titer.
Jianlin XU, Qin HE, Mengmeng XU, Matthew Stephen REHMANN, Charles Anthony HILL, Christopher Louis OLIVEIRA, Michael Christopher BORYS, Zhengjian LI, Shun ZHENG
Filed: 30 Jul 20
Utility
Methods of Treating Atopic Dermatitis
29 Sep 22
The present disclosure is directed to methods of treating atopic dermatitis comprising administering to a subject in need thereof a therapeutically effective amount of an anti-IL-13 antibody, or antigen binding fragment thereof, thereby treating atopic dermatitis in the subject.
Sarah Harris, Erin Babcock, Cristian Rodriguez
Filed: 16 Mar 22
Utility
Radioligands for Imaging the ID01 Enzyme
29 Sep 22
The present invention relates to radiolabeled IDO1 inhibitors or pharmaceutically acceptable salts thereof which are useful for the quantitative imaging of IDO enzymes in mammals.
David J. Donnelly, Erin Lee Cole, Richard Charles Burrell, Wesley A. Turley, Alban J. Allentoff, Michael Arthur Wallace, James Aaron Balog, Audris Huang, Mette Skinbjerg
Filed: 18 Apr 22
Utility
AGONISTS OF ROR GAMMAt
29 Sep 22
Lalgudi S. Harikrishnan, Peter Kinam Park, Zheming Ruan, Donna D. Wei, Daniel O'Malley, Honghe Wan, Ashok Vinayak Purandare, Brian E. Fink
Filed: 5 Aug 20
Utility
ANTI-PD-1 Antibody In Combination with an ANTI-CD30 Antibody In Cancer Treatment
22 Sep 22
This disclosure provides methods for treating a tumor in a subject comprising administering to the subject an anti-PD-1 antibody and an anti-CD30 antibody.
Benedetto FARSACI, Neil JOSEPHSON, Anthony CAO, Ryan HEISER
Filed: 7 Apr 22
Utility
Methods of Treating Prostate Cancer
22 Sep 22
The present application relates generally to methods for treating prostate cancer with substituted tricyclic derivative is 2-[3-(1,4-dimethyl-1H-1,2,3-triazol-5-yl)-5-[(S)-(oxan-4-yl)(phenyl)methyl]-5H-pyrido[3,2-b]indol-7-yl]propan-2-ol as a bromodomain inhibitor, or the pharmaceutically acceptable salt thereof.
Martina Malatesta, Ellen Hope Filvaroff
Filed: 7 Mar 22
Utility
PSGL-1 Antagonists and Uses Thereof
22 Sep 22
Methods of identifying and using PSGL-1 antagonists are provided.
Robert J. Johnston, Andrew Rankin, Arathi Krishnakumar, Paul O. Sheppard, Arvind Rajpal
Filed: 15 Mar 22
Utility
Process for Preparing Carbamoyloxymethyl Triazole Cyclohexyl Acid Compounds
22 Sep 22
Richard J. Fox, Carlos A. Guerrero, Michael Dummeldinger, Dimitri Skliar, Harshkumar Patel, Yichen Tan, David Thomas George
Filed: 14 Apr 20
Utility
Biaryl Dialkyl Phosphine Oxide FPR2 Agonists
22 Sep 22
Pravin Sudhakar Shirude, Amit Kumar Chattopadhyay, Ellen K. Kick, Nicholas R. Wurtz
Filed: 16 Jun 20
Utility
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
20 Sep 22
James Aaron Balog, Steven P. Seitz, David K. Williams, Murugaiah Andappan Murugaiah Subbaiah
Filed: 3 Jan 19
Utility
Substituted indole compounds useful as inhibitors of TLR7/8/9
20 Sep 22
Alaric J. Dyckman, Dharmpal S. Dodd, Tasir Shamsul Haque, Brian K. Whiteley, John L. Gilmore
Filed: 3 Aug 18
Utility
Isoxazole N-linked carbamoyl cyclohexyl acids as LPA antagonists
20 Sep 22
Peter Tai Wah Cheng, Yan Shi, Robert F. Kaltenbach, III, Ying Wang, Hao Zhang
Filed: 18 Dec 18
Utility
Spiroheptanyl hydantoins as rock inhibitors
20 Sep 22
Benjamin P. Vokits, Scott A. Shaw
Filed: 11 Jul 18
Utility
Fibronectin based scaffold proteins
20 Sep 22
Fibronectin type III (10Fn3) binding domains having novel designs that are associated with reduced immunogenicity are provided.
Dasa Lipovsek, Jonathan H. Davis
Filed: 10 Jan 20
Utility
Antisense oligonucleotides targeting alpha-synuclein and uses thereof
20 Sep 22
The present disclosure relates to antisense oligonucleotides, which target SNCA mRNA (e.g., at an intron exon junction) in a cell, leading to reduced expression of SNCA protein.
Richard E. Olson, Angela M. Cacace, Jere E. Meredith, Jr., Nino Devidze, James K. Loy, Carl J. Baldick, Annapurna Pendri, Ivar M. McDonald, Peter Hagedorn, Marianne Lerbech Jensen
Filed: 11 Jan 19
Utility
NLRP3 Modulators
15 Sep 22
This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that modulate (e.g., agonizes or partially agonizes) NLRP3 that are useful, e.g., for treating a condition, disease or disorder in which an increase in NLRP3 signaling may correct a deficiency in innate immune activity (e.g., a condition, disease or disorder associated with an insufficient immune response) that contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human).
Gary D. Glick, Shomir Ghosh, William R. Roush, Edward James Olhava, Daniel O'Malley
Filed: 6 May 21
Utility
Substituted Benzimidazolone Compounds
15 Sep 22
Alaric J. DYCKMAN, Laxman Pasunoori, Sreekantha Ratna Kumar, Srinivasan Kunchithaptham Duraisamy, Pitani Veera Venkata Srinivas, Vikram Bhogadi, Subramanya Hegde
Filed: 7 May 20